"TAP não sobrevive se se mantiver pública", garante Pinto Luz

[mapaman]

Concordo com parte do que dizes, não vale a pena grandes alaridos.

Compraste?? Vendeste?? ainda bem para quem o fez, mas mais ninguem precisa saber disso.

Agora quando falas em coisas manhosas, ai não posso concordar.....ja acompanho este titulo desde 2005 e posso dizer que ja me deu muitas alegrias no passado, nomeadamente em 2006.
Espero que isto se venha a repetir.

Aqui fica o motivo desta subida.

Generex Announces USFDA Approval of Use of Company's Flagship Buccal Insulin Product, Generex Oral-lyn(TM), Under the USFDA'S Treatment Investigational New Drug (IND) Program
THURSDAY, SEPTEMBER 10, 2009 9:01 AM
- GlobeNewswire



WORCESTER, Mass., Sep 10, 2009 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the treatment use of Generex Oral-lyn(tm) under the FDA's Treatment Investigational New Drug (IND) program.

The FDA's Treatment IND program allows companies to provide early access to investigational drugs for patients with serious or life-threatening conditions for which there is no satisfactory alternative treatment. Drugs that are granted approval by the FDA for the Treatment IND program must demonstrate the prospect of efficacy through clinical testing.

Under a structured Treatment IND protocol, Generex Oral-lyn(tm) will be provided to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for the treatment of diabetes, and who are not eligible to participate in the Company's ongoing global Phase III pivotal clinical trial.

This Treatment IND will be open to eligible patients that comply with the inclusion/exclusion criteria of the protocol, including those who are taking currently approved anti-diabetic medications. There are no oral or injectable medications contraindicated for this IND program.

In order to learn more about the availability of Generex Oral-lyn(tm) under the IND Treatment program, as per FDA requirements, the Company will be providing information within the www.ClinicalTrials.gov website. Details will include study design and participating sites and/or physicians. Please note that the drug will be available only through physicians who are registered in the Treatment IND program.

"We are excited about having the opportunity to meet the needs of American patients living with diabetes who have no satisfactory alternative treatment and have contacted the Company, based on their special needs, about possible access to Generex Oral-lyn(tm)," stated Anna Gluskin, Generex's President and Chief Executive Officer. "This opportunity to provide those in critical need of Generex Oral-lyn(tm) will continue while the pivotal Phase III study concludes and the Company prepares for its New Drug Submission with the USFDA and other major health authorities in key markets."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

This news release was distributed by GlobeNewswire, www.globenewswire.com

Abraços
Shevet

"Manhosas" no sentido de imprevisiveis...

de resto,é negociável como qualquer outra.

cumps

[Shevet]

Concordo com parte do que dizes, não vale a pena grandes alaridos.

Compraste?? Vendeste?? ainda bem para quem o fez, mas mais ninguem precisa saber disso.

Agora quando falas em coisas manhosas, ai não posso concordar.....ja acompanho este titulo desde 2005 e posso dizer que ja me deu muitas alegrias no passado, nomeadamente em 2006.
Espero que isto se venha a repetir.

Aqui fica o motivo desta subida.

Generex Announces USFDA Approval of Use of Company's Flagship Buccal Insulin Product, Generex Oral-lyn(TM), Under the USFDA'S Treatment Investigational New Drug (IND) Program
THURSDAY, SEPTEMBER 10, 2009 9:01 AM
- GlobeNewswire



WORCESTER, Mass., Sep 10, 2009 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the treatment use of Generex Oral-lyn(tm) under the FDA's Treatment Investigational New Drug (IND) program.

The FDA's Treatment IND program allows companies to provide early access to investigational drugs for patients with serious or life-threatening conditions for which there is no satisfactory alternative treatment. Drugs that are granted approval by the FDA for the Treatment IND program must demonstrate the prospect of efficacy through clinical testing.

Under a structured Treatment IND protocol, Generex Oral-lyn(tm) will be provided to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for the treatment of diabetes, and who are not eligible to participate in the Company's ongoing global Phase III pivotal clinical trial.

This Treatment IND will be open to eligible patients that comply with the inclusion/exclusion criteria of the protocol, including those who are taking currently approved anti-diabetic medications. There are no oral or injectable medications contraindicated for this IND program.

In order to learn more about the availability of Generex Oral-lyn(tm) under the IND Treatment program, as per FDA requirements, the Company will be providing information within the www.ClinicalTrials.gov website. Details will include study design and participating sites and/or physicians. Please note that the drug will be available only through physicians who are registered in the Treatment IND program.

"We are excited about having the opportunity to meet the needs of American patients living with diabetes who have no satisfactory alternative treatment and have contacted the Company, based on their special needs, about possible access to Generex Oral-lyn(tm)," stated Anna Gluskin, Generex's President and Chief Executive Officer. "This opportunity to provide those in critical need of Generex Oral-lyn(tm) will continue while the pivotal Phase III study concludes and the Company prepares for its New Drug Submission with the USFDA and other major health authorities in key markets."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

This news release was distributed by GlobeNewswire, www.globenewswire.com

Abraços
Shevet

[mapaman]

loucura total!! esta a subir 50%!!!!!!!!!!!!!

http://finance.yahoo.com/news/Generex-A ... l?x=0&.v=1

Ou muito me engano ou vão começar a aparecer por ai mais posts destes...

Claro que no dia em que cenas manhosas como esta abrirem a cair 80% enfiam a viola no saco e nunca mais aparecem.

cumps

[pedro200]

Ok, obrigado pela informação.

Mas já etsou fora. Sai a 0,95!

Bons trades.

[kuby]

pedro200

Eu estaria atento a um fecho consistente acima dos 0,8 para avaliar a possibilidade de novos patamares, com stop nos 0,7 caso recue.

Cumps

Kuby

[jcms]

Vendidas a ,99 USD

[Ulisses Pereira]

Pedro, peço-te que não transformes isto num relato. Hoje em dia, as pessoas têm acesso às cotações, o importante é o "sumo".

Um abraço,
Ulisses

[pedro200]

uma rápida análise técnica, please!

thanks

[pedro200]

loucura total!! esta a subir 50%!!!!!!!!!!!!!

http://finance.yahoo.com/news/Generex-A ... l?x=0&.v=1

[pedro200]

entrei ontem a 0,67

[pedro200]

http://finance.yahoo.com/q?s=GNBT

ontem subiu 10% e hoje sobe fortemente na pré-abertura.

nos ultimos meses conseguiram segurá-la na casa dos 0,6. Houve forte acumulação. Agora está pronta para o ataque ao 1 dólar.